[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-461615-105":59,"doc-detail-461615-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","association-between-lipid-lowering-therapy-and-differences-in-the-distribution-of-ldl-c-apob-and-non-hdl-c","Association Between Lipid-Lowering Therapy and Differences in the Distribution of LDL-C, apoB and non-HDL-C","","Background: Hypercholesterolemia diagnosis depends on laboratory lipid parameters. This retrospective study assessed how low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) distributions differ by the presence and type of lipid-lowering therapy (LLT). Methods: Consecutive patients with LDL-C, apoB, and non-HDL-C measurements between March and November 2024 were analyzed using ESC cut-off-based categorizations. Results: 5048 patients were included; among LLT users, 77.3% were on statin monotherapy and 22.7% on combined therapy. Discordance patterns favored fewer discrepancies with combined LLT. Conclusions: Classifying hyperlipidemia by LDL-C, non-HDL-C, and apoB shows significant marker discrepancies, reduced by LLT.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-between-lipid-lowering-therapy-and-differences-in-the-distribution-of-ldl-c-apob-and-non-hdl-c/461615/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-between-lipid-lowering-therapy-and-differences-in-the-distribution-of-ldl-c-apob-and-non-hdl-c/461615.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main purpose of this study?","Question",{"text":113,"@type":114},"To evaluate differences in the distribution of LDL-C, non-HDL-C, and apoB concentrations according to the presence and type of lipid-lowering therapy (LLT).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants and lipid measurements selected?",{"text":118,"@type":114},"The study retrospectively included consecutive patients with at least one measurement of LDL-C, apoB, and non-HDL-C between March and November 2024 in a tertiary hospital, using ESC guideline cut-offs.",{"name":120,"@type":111,"acceptedAnswer":121},"Did LLT affect discrepancies between lipid markers?",{"text":122,"@type":114},"Yes. Discordance between on-target apoB and elevated LDL-C occurred in fewer patients among treated groups, and LLT—especially combined therapy—reduced discrepancies more effectively.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},461615,1790794875,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nAssociation Between Lipid-Lowering Therapy and Differences in the Distribution of LDL-C, apoB and non-HDL-C  \nMarcin Ziółkowski 1,†, Karolina Obo ´nska 2, *,†, Jakub Ratajczak 2, Piotr Adamski 2, Maciej Banach 3,4,5,6, Krzysztof Chlebus 7, Klaudyna Grzelakowska 2, Piotr Jankowski 8,9, Magdalena Krintus 2, Jacek Kry´s 1, Ewa Laskowska 2, Natalia Mrzywka 10, Piotr Niezgoda 2, Małgorzata Ostrowska 2, Przemysław Podhajski 2, Grzegorz Skonieczny 11, Boena Sosnowska 4, Łukasz Szarpak 12,13,14, Małgorzata Topolska 15, Julia Umi ´nska 2, Alicja Rzepka-Cholasi ´nska 2, Eliano Pio Navarese 2 and Jacek Kubica 2  \nAcademic Editor: Cyrus V. DeSouza  \nReceived: 31 October 2025  \nRevised: 10 December 2025  \nAccepted: 12 December 2025  \nPublished: 20 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Antoni Jurasz University Hospital No. 1 in Bydgoszcz, 85-094 Bydgoszcz, Poland;  \n[m.ziolkowski@jurasza.pl](m.ziolkowski@jurasza.pl) (M.Z.); [jacek.krys@gmail.com](jacek.krys@gmail.com) (J.K.)  \n2 Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland; [jakub.ratajczak@cm.umk.pl](jakub.ratajczak@cm.umk.pl) (J.R.); [piotr.adamski@cm.umk.pl](piotr.adamski@cm.umk.pl) (P.A.); [klaudyna.grzelakowska@gmail.com](klaudyna.grzelakowska@gmail.com) (K.G.); [krintus@cm.umk.pl](krintus@cm.umk.pl) (M.K.); [ewa.laskowska@cm.umk.pl](ewa.laskowska@cm.umk.pl) (E.L.); [piotr.niezgoda@cm.umk.pl](piotr.niezgoda@cm.umk.pl) (P.N.); [m.ostrowska@cm.umk.pl](m.ostrowska@cm.umk.pl) (M.O.); [przemyslaw.podhajski@cm.umk.pl](przemyslaw.podhajski@cm.umk.pl) (P.P.); [julia.uminska@cm.umk.pl](julia.uminska@cm.umk.pl) (J.U.); [alicja.rzepka@cm.umk.pl](alicja.rzepka@cm.umk.pl) (A.R.-C.); [elianonavarese@gmail.com](elianonavarese@gmail.com) (E.P.N.); [jkubica@cm.umk.pl](jkubica@cm.umk.pl) (J.K.)  \n3 Faculty of Medicine, The John Paul II Catholic University of Lublin (KUL), 20-950 Lublin, Poland; [maciej.banach@icloud.com](maciej.banach@icloud.com)  \n4 Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), 90-419 Lodz, Poland; [bozena.sosnowska@umed.lodz.pl](bozena.sosnowska@umed.lodz.pl)  \n5 Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA  \n6 Liverpool Centre for Cardiovascular Science (LCCS), Liverpool L7 8TX, UK  \n7 First Department of Cardiology, Medical University of Gdansk, 80-210 Gdansk, Poland; [krzysztof.chlebus@gumed.edu.pl](krzysztof.chlebus@gumed.edu.pl)  \n8 Department of Internal Medicine and Geriatric Cardiology, Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland; [piotrjankowski@interia.pl](piotrjankowski@interia.pl)  \n9 Department of Epidemiology and Health Promotion, School of Public Health, Centre of Postgraduate Medical Education, 01-826 Warsaw, Poland  \n10 American Heart of Poland, 64-920 Pila, Poland; [natalia.mrzywka@onet.eu](natalia.mrzywka@onet.eu)  \n11 Department of Cardiology and Intensive Cardiac Care Unit, District Polyclinic Hospital, 87-100 Torun, Poland; [grzegorz.skonieczny@onet.eu](grzegorz.skonieczny@onet.eu)  \n12 Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin (KUL), 20-950 Lublin, Poland; [lukasz.szarpak@gmail.com](lukasz.szarpak@gmail.com)  \n13 Department of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland  \n14 Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA  \n15 American Heart of Poland, 40-028 Katowice, Poland; [malgorzata.topolska@ahop.pl](malgorzata.topolska@ahop.pl)  \n* Correspondence: [k.obonska@cm.umk.pl](k.obonska@cm.umk.pl); Tel.: +48-52-585-40-23 † These authors contributed equally to this work.  \nAbstract  \nBackground: The diagnosis of hypercholesterole","cbCaihBJpoIbCgqA","https://ap.wps.com/l/cbCaihBJpoIbCgqA","pdf",2261900,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What was the main purpose of this study?\",\"answer\":\"To evaluate differences in the distribution of LDL-C, non-HDL-C, and apoB concentrations according to the presence and type of lipid-lowering therapy (LLT).\"},{\"question\":\"How were participants and lipid measurements selected?\",\"answer\":\"The study retrospectively included consecutive patients with at least one measurement of LDL-C, apoB, and non-HDL-C between March and November 2024 in a tertiary hospital, using ESC guideline cut-offs.\"},{\"question\":\"Did LLT affect discrepancies between lipid markers?\",\"answer\":\"Yes. Discordance between on-target apoB and elevated LDL-C occurred in fewer patients among treated groups, and LLT—especially combined therapy—reduced discrepancies more effectively.\"}]","Association Between Lipid-Lowering Therapy and Differences in the Distribution of LDL-C, apoB and non-HDL-C | PDF",1790761977,35]